Vanessa Raymont
MBChB MSc MRCPsych
Senior Clinical Researcher, R&D Director Oxford Health NHS Foundation Trust
- Honorary Senior Clinical Research Fellow, Centre of Dementia Prevention, University of Edinburgh
- Honorary Consultant Psychiatrist
My clinical and research interests are in traumatic brain injury, and memory disorders and dementia, as well as clinical trials in cognitive impairment, having worked for over 20 years in clinical trials in the UK and US.
I am currently the Principal Investigator for the New Therapeutics in Alzheimer’s Disease (NTAD), Brains for Dementia Research (BDR) and 7Tesla MRI Scanning in Alzheimer’s disease and Frontotemporal Lobar Degeneration studies and Chief Investigator on the Deep and Frequent Phenotyping (DFP) study and a NHIR-funded study assessing the use of sertraline to prevent post-head injury depression. I am co-lead for the Clinical Trials section of Oxford Translational Neuroscience and Dementia Research Group and NIHR Dementia and Mental Health Lead for the Thames Valley and South Midlands Clinical Research Network. I am an associate director of Dementia Platforms UK, and workstream lead for the Trials Delivery Framework. I serve as a Commissioner for the Commission on Human Medicines.
Recent publications
-
Journal article
Blane J. et al, (2021), Alzheimers Dement, 17 Suppl 11
-
Journal article
Lennon MJ. et al, (2021), J Alzheimers Dis
-
Journal article
Delanerolle G. et al, (2021), EClinicalMedicine, 38, 101016 - 101016
-
Journal article
Burns DK. et al, (2021), The Lancet Neurology, 20, 537 - 547
-
Journal article
Delanerolle G. et al, (2021), Women's health (London, England), 17, 17455065211019717 - 17455065211019717
-
Journal article
Phiri P. et al, (2021), EClinicalMedicine, 34
-
Journal article
Delanerolle G. et al, (2021), World J Psychiatry, 11, 58 - 62
-
Journal article
Baksh RA. et al, (2021), Psychol Aging, 36, 288 - 297
-
Journal article
Mendis SB. et al, (2021), Front Neurol, 12